AIMS: This prospective study investigated the effect of genetic polymorphisms in a biotransformation enzyme (CYP3A5) and a transporter protein (ABCB1) on tacrolimus (Tac) whole blood concentrations in renal transplantation, and more specifically on peripheral blood mononuclear cell (PBMC) drug concentrations, after renal transplantation. MATERIALS & METHODS: A total of 96 renal transplant recipients were genotyped for the exon 11 (1199G>A), 21 (3435C>T) and 26 (2677G>T/A) polymorphisms in the ABCB1 gene and for the intron 3 polymorphism in the CYP3A5 gene. Tac blood and PBMC concentrations were determined at day 7 after transplantation and at steady state, and then compared with recipient genotypes. RESULTS & CONCLUSION: The ABCB1 1199G>A, 3435C>T and 2677G>T/A SNPs, appeared to reduce the activity of P-glycoprotein towards Tac, increasing Tac PBMC concentrations. The impact of ABCB1 genetic polymorphisms on Tac blood concentrations was negligible. As increased Tac intracellular concentrations might in turn enhance immunosuppressive status and prevention or rejection, ABCB1 recipient genotyping might be useful to better individualize the Tac immunosuppressive therapy in renal transplantation.
AIMS: This prospective study investigated the effect of genetic polymorphisms in a biotransformation enzyme (CYP3A5) and a transporter protein (ABCB1) on tacrolimus (Tac) whole blood concentrations in renal transplantation, and more specifically on peripheral blood mononuclear cell (PBMC) drug concentrations, after renal transplantation. MATERIALS & METHODS: A total of 96 renal transplant recipients were genotyped for the exon 11 (1199G>A), 21 (3435C>T) and 26 (2677G>T/A) polymorphisms in the ABCB1 gene and for the intron 3 polymorphism in the CYP3A5 gene. Tac blood and PBMC concentrations were determined at day 7 after transplantation and at steady state, and then compared with recipient genotypes. RESULTS & CONCLUSION: The ABCB1 1199G>A, 3435C>T and 2677G>T/A SNPs, appeared to reduce the activity of P-glycoprotein towards Tac, increasing Tac PBMC concentrations. The impact of ABCB1 genetic polymorphisms on Tac blood concentrations was negligible. As increased Tac intracellular concentrations might in turn enhance immunosuppressive status and prevention or rejection, ABCB1 recipient genotyping might be useful to better individualize the Tac immunosuppressive therapy in renal transplantation.
Authors: Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2013-10 Impact factor: 2.089
Authors: Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik Journal: Br J Clin Pharmacol Date: 2014-04 Impact factor: 4.335
Authors: P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani Journal: Eur J Clin Pharmacol Date: 2011-11-20 Impact factor: 2.953
Authors: Franc Andreu; Helena Colom; Laure Elens; Teun van Gelder; Ronald H N van Schaik; Dennis A Hesselink; Oriol Bestard; Joan Torras; Josep M Cruzado; Josep M Grinyó; Nuria Lloberas Journal: Clin Pharmacokinet Date: 2017-08 Impact factor: 6.447
Authors: Olivia Campagne; Donald E Mager; Daniel Brazeau; Rocco C Venuto; Kathleen M Tornatore Journal: J Clin Pharmacol Date: 2018-05-18 Impact factor: 3.126